Web-based references relating to the number under the disk sign, listed by page header
Liver tumours
105 No link available ; page 262
106 Current
techniques and results of liver resection for colorectal liver metastases.
Author: Hamady ZZ, Kotru A, Nishio H, Lodge JP. Journal: Br Med Bull; 2004 ;
70():87-104. PubMed ID: 15509717.
[Link]
; page 262
107 Local/regional and systemic treatments of
hepatocellular carcinoma. Author: Beaugrand M, N'kontchou G, Seror O, Ganne N,
Trinchet JC. Journal: Semin Liver Dis; 2005 ; 25(2):201-11. PubMed ID: 15918148.
[Link]
; page 262
108 Synergistic interaction between aflatoxin B1
and hepatitis B virus in hepatocarcinogenesis. Author: Kew MC. Journal: Liver
Int; 2003 Dec ; 23(6):405-9. PubMed ID: 14986813.
[Link]
; page 262
109 Issues in screening and surveillance for
hepatocellular carcinoma. Author: Di Bisceglie AM. Journal: Gastroenterology;
2004 Nov ; 127(5 Suppl 1):S104-7. PubMed ID: 15508072.
[Link]
; page 262
110 No link available; page 262
111 Liver fluke
infection and cholangiocarcinoma: model of endogenous nitric oxide and
extragastric nitrosation in human carcinogenesis. Author: Haswell-Elkins MR,
Satarug S, Tsuda M, Mairiang E, Esumi H, Sithithaworn P, Mairiang P, Saitoh M,
Yongvanit P, Elkins DB. Journal: Mutat Res; 1994 Mar 1 ; 305(2):241-52. PubMed
ID: 7510035. Abstract
[Link]
; page 262
112 Diagnosis and surgical treatment of primary
hepatic cholangiocarcinoma. Author: Han SL, Zhu GB, Yao JG, Lan SH, Shao YF.
Journal: Hepatogastroenterology; 2005 Mar-Apr ; 52(62):348-51. PubMed ID:
15816432.
[Link]
; page 262
113 Outcome after resection of central
cholangiocarcinoma: preliminary experience with 46 patients in a single center.
Author: Wahab MA, Sultan A, Elgwalby N, Fathy O, Abo zied M, Aboelenen A, Fouad
A, Abd alla T, Kandel T, Elshobary M, Elfiky A, el Ebidby G, Gad el Hak NG, Ezzat
F. Journal: Hepatogastroenterology; 2003 Mar-Apr ; 50(50):337-41. PubMed ID:
12749216. Abstract
[Link]
; page 262
(footnote) Hepatitis
B viremia is associated with increased risk of hepatocellular carcinoma in
chronic carriers. Author: Tang B, Kruger WD, Chen G, Shen F, Lin WY, Mboup S,
London WT, Evans AA. Journal: J Med Virol; 2004 Jan ; 72(1):35-40. PubMed ID:
14635008.
[Link]; page 262
114 The United Kingdom's hepatitis B immunisation
strategy--where now? Author: Goldberg D, McMenamin J. Journal: Commun Dis Public
Health; 1998 Jun ; 1(2):79-83. PubMed ID: 9644118.
[Link]
; page 263
Ulcerative colitis (UC)
115 [Secondary amyloidosis in ulcerative
colitis--successful treatment with colchicine] Author: Menges M, Steffen HM.
Journal: Z Gastroenterol; 1996 Nov ; 34(11):753-6. PubMed ID: 9045537.
[Link]
; page 264
116 Venous thromboembolism in inflammatory bowel
disease. Author: Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Journal: Am J
Gastroenterol; 2004 Jan ; 99(1):97-101. PubMed ID: 14687149.
[Link]
; page 264
117No link available; page 264
118
Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis.
Author: Inadomi JM. Journal: Scand J Gastroenterol Suppl; 2003 ; (237):17-21.
PubMed ID: 12797675.
[Link]
; page 264
118 Strategies for detecting colon cancer and/or
dysplasia in patients with inflammatory bowel disease. Author: Mpofu C, Watson
AJ, Rhodes JM. Journal: Cochrane Database Syst Rev; 2004 ; (2):CD000279. PubMed
ID: 15106148.
[Link]
; page 264
119 No link available; page 264
(footnote) Afa/Dr
diffusely adhering Escherichia coli infection in T84 cell monolayers induces
increased neutrophil transepithelial migration, which in turn promotes
cytokine-dependent upregulation of decay-accelerating factor (CD55), the
receptor for Afa/Dr adhesins. Author: B"s F, Brest P, Hofman V, Guignot J,
Kansau I, Rossi B, Servin A, Hofman P. Journal: Infect Immun; 2003 Apr ;
71(4):1774-83. PubMed ID: 12654791.
[Link]; page 264
[Link]
; page 265
120 Rectal
aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Author:
Marshall JK, Irvine EJ. Journal: Aliment Pharmacol Ther; 1995 Jun ;
9(3):293-300. PubMed ID: 7654892.
121 Ileocecal valve-preserving ileostomy after
total proctocolectomy--a novel technique for ileostomy. Author: Nio Y, Itakura
M, Yamaguchi K, Hirahara N. Journal: Dig Surg; 2004 ; 21(1):7-9. PubMed ID:
14639037.
[Link]
; page 265
122 The diagnosis and treatment of pouchitis in
inflammatory bowel disease. Author: Cheifetz A, Itzkowitz S. Journal: J Clin
Gastroenterol; 2004 May-Jun ; 38(5 Suppl):S44-50. PubMed ID: 15115932.
[Link]
; page 265
123 Cyclosporine A for induction of remission in
severe ulcerative colitis. Author: Shibolet O, Regushevskaya E, Brezis M,
Soares-Weiser K. Journal: Cochrane Database Syst Rev; 2005 ; (1):CD004277.
PubMed ID: 15674937.
[Link]
; page 265
124 Infliximab as rescue therapy in severe to
moderately severe ulcerative colitis: a randomized, placebo-controlled study.
Author: J"erot G, Hertervig E, Friis-Liby I, Blomquist L, Karl"P, Gr"" C,
Vilien M, Str"m M, Danielsson A, Verbaan H, Hellstr"m PM, Magnuson A, Curman B.
Journal: Gastroenterology; 2005 Jun ; 128(7):1805-11. PubMed ID: 15940615.
[Link]
; page 265
125 Transdermal nicotine for induction of
remission in ulcerative colitis. Author: McGrath J, McDonald JW, Macdonald JK.
Journal: Cochrane Database Syst Rev; 2004 ; (4):CD004722. PubMed ID: 15495126.
[Link]
; page 265
126 No link available; page 265
127; page Oral
5-aminosalicylic acid for induction of remission in ulcerative colitis. Author:
Sutherland L, MacDonald JK. Journal: Cochrane Database Syst Rev; 2003 ;
(3):CD000543. PubMed ID: 12917894.
[Link]
; page 265
128 Pathology of indeterminate colitis. Author:
Odze RD. Journal: J Clin Gastroenterol; 2004 May-Jun ; 38(5 Suppl):S36-40.
PubMed ID: 15115930.
[Link]
; page 265
(footnote) Budesonide
versus prednisolone retention enemas in active distal ulcerative colitis.
Author: L"fberg R, Ostergaard Thomsen O, Langholz E, Schi"ler R, Danielsson A,
Suhr O, Graffner H, P"man L, Matzen P, M"ller-Petersen JF. Journal: Aliment
Pharmacol Ther; 1994 Dec ; 8(6):623-9. PubMed ID: 7696452.
[Link]; page 264
Crohn’s disease
129 Perianal Crohn's disease and infliximab
therapy. Author: McNamara DA, Brophy S, Hyland JM. Journal: Surgeon; 2004 Oct ;
2(5):258-63. PubMed ID: 15570844.
[Link]
; page 266
(footnote) Biocompatibility
of micro- and nano-particles in the colon. Part II. Author: Gatti AM. Journal:
Biomaterials; 2004 Feb ; 25(3):385-92. PubMed ID: 14585686.
[Link]; page 266
(footnote) Card15
gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's
disease colon. Author: Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre
F, De Lagausie P, Yang C, Desreumaux P, Giovannini M, C"rd JP, Zouali H,
Emilie D, Peuchmaur M. Journal: Gut; 2003 Jun ; 52(6):840-6. PubMed ID:
12740340.
[Link]; page 266
(footnote) Crohn
BB, Ginzburg L and Oppenheimer GD; Regional Ileitis: A Pathologic and Clinical
Entity. JAMA 1932 (Oct 15) 99:1323-1329.
[Link]; page 266
(footnote) Integrating
theories of the etiology of Crohn's disease. On the etiology of Crohn's disease:
questioning the hypotheses. Author: Chamberlin WM, Naser SA. Journal: Med Sci
Monit; 2006 Feb ; 12:RA27-33. PubMed ID: 16449960.
[Link]; page 266
130 Azathioprine for maintaining remission of
Crohn's disease. Author: Pearson DC, May GR, Fick G, Sutherland LR. Journal:
Cochrane Database Syst Rev; 2000 ; (2):CD000067. PubMed ID: 10796482.
[Link]
; page 267
131 Oral 5-aminosalicylic acid for maintenance of
medically-induced remission in Crohn's Disease. Author: Akobeng AK, Gardener E.
Journal: Cochrane Database Syst Rev; 2005 ; (1):CD003715. PubMed ID: 15674913.
[Link]
; page 267
132 Enteral nutritional therapy for inducing
remission of Crohn's disease. Author: Zachos M, Tondeur M, Griffiths AM.
Journal: Cochrane Database Syst Rev; 2001 ; (3):CD000542. PubMed ID: 11686966.
[Link]
; page 267
133 Methotrexate for induction of remission in
refractory Crohn's disease. Author: Alfadhli AA, McDonald JW, Feagan BG.
Journal: Cochrane Database Syst Rev; 2005 ; (1):CD003459. PubMed ID: 15674908.
[Link]
; page 267
134 Management of the short bowel syndrome after
extensive small bowel resection. Author: Keller J, Panter H, Layer P. Journal:
Best Pract Res Clin Gastroenterol; 2004 Oct ; 18(5):977-92. PubMed ID: 15494290.
[Link]
; page 267
135 Tumor necrosis factor-alpha antibody for
induction of remission in Crohn's disease. Author: Akobeng AK, Zachos M.
Journal: Cochrane Database Syst Rev; 2004 ; (1):CD003574. PubMed ID: 14974022.
[Link]
; page 267
136 Infliximab maintenance therapy for
fistulizing Crohn's disease. Author: Sands BE, Anderson FH, Bernstein CN, Chey
WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE,
Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA,
van Deventer SJ. Journal: N Engl J Med; 2004 Feb 26 ; 350(9):876-85. PubMed ID:
14985485.
[Link]
; page 267
137; page Efficacy and safety of retreatment with
anti-tumor necrosis factor antibody (infliximab) to maintain remission in
Crohn's disease. Author: Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E,
Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL,
Schaible TF, Van Deventer SJ. Journal: Gastroenterology; 1999 Oct ;
117(4):761-9. PubMed ID: 10500056.
[Link]
; page 267
138 Health Technol Assess. 2003;7(3):1 Systematic
review and economic evaluation of the effectiveness of infliximab for the
treatment of Crohn's disease. Clark W
[Link]
; page 267
139 No link available; page 267
